<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ceftazidime</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00438</strong>&#160; (APRD00857)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Semisynthetic, broad-spectrum antibacterial derived from cephaloridine and used especially for Pseudomonas and other gram-negative infections in debilitated patients. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00438/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00438/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00438.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00438.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00438.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00438.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00438.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00438">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ceftazidim</td><td>German</td><td>INN</td></tr><tr><td>Ceftazidima</td><td>Spanish</td><td>INN</td></tr><tr><td>Ceftazidime</td><td>French</td><td>INN</td></tr><tr><td>Ceftazidimum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Ceftazidime pentahydrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT001024/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT001024/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT001024">DBSALT001024</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cefzim</td><td>Pharco B International</td></tr><tr><td>Ceptaz</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Fortaz</td><td>GlaxoSmithKline</td></tr><tr><td>Fortum</td><td>GlaxoSmithKline</td></tr><tr><td>Tazicef</td><td>Hospira</td></tr><tr><td>Tazidime</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Veltadim</td><td>Novell</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li>
<li><a href="/mesh/cephalosporins">Cephalosporins</a></li></ul></td></tr><tr><th>CAS number</th><td>78439-06-2</td></tr><tr><th>Weight</th><td>Average: 546.576<br>Monoisotopic: 546.099138468</td></tr><tr><th>Chemical Formula</th><td>C<sub>22</sub>H<sub>22</sub>N<sub>6</sub>O<sub>7</sub>S<sub>2</sub></td></tr><tr><th>InChI Key</th><td>ORFOPKXBNMVMKC-DWVKKRMSSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[O-]C(=O)C1=C(CS[C@]2([H])[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C3=CSC(N)=N3)C(=O)N12)C[N+]1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Lactams</td></tr><tr><th>Subclass</th><td>Beta Lactams</td></tr><tr><th>Direct parent</th><td>Cephalosporins</td></tr><tr><th>Alternative parents</th><td>N-acyl-alpha Amino Acids and Derivatives; Alpha Amino Acid Amides; 2,4-disubstituted Thiazoles; Pyridinium Derivatives; 1,3-Thiazines; Primary Aromatic Amines; Dicarboxylic Acids and Derivatives; Aminothiazoles; Tertiary Carboxylic Acid Amides; Hemiaminals; Secondary Carboxylic Acid Amides; Azetidines; Tertiary Amines; Oxime Ethers; Carboxylic Acids; Enamines; Enolates; Polyamines; Aminals; Thioethers; Carboxylic Acid Salts; Imines</td></tr><tr><th>Substituents</th><td>n-acyl-alpha amino acid or derivative; alpha-amino acid amide; alpha-amino acid or derivative; 2,4-disubstituted 1,3-thiazole; pyridinium; meta-thiazine; pyridine; primary aromatic amine; 1,3-thiazolamine; dicarboxylic acid derivative; tertiary carboxylic acid amide; azole; thiazole; secondary carboxylic acid amide; carboxamide group; tertiary amine; azetidine; hemiaminal; oxime ether; polyamine; carboxylic acid salt; enolate; enamine; thioether; carboxylic acid; aminal; carboxylic acid derivative; imine; amine; organonitrogen compound; primary amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moeity or a derivative thereof.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).</td></tr><tr><th>Pharmacodynamics</th><td>Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis, primarily penicillin binding protein 3 (PBP3). A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins. Ceftazidime has activity against the gram-negative organisms <i>Pseudomonas</i> and <i>Enterobacteriaceae</i>. Its activity against <i>Pseudomonas</i> is a distinguishing feature of ceftazidime among the cephalosporins.</td></tr><tr><th>Mechanism of action</th><td>The bactericidal activity of ceftazidime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).</td></tr><tr><th>Absorption</th><td>The absorption of ceftazidime is directly proportional to the size of the dose.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td>The elimination of ceftazidime by the kidneys resulted in high therapeutic concentrations in the urine.</td></tr><tr><th>Half life</th><td>Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.</td></tr><tr><th>Clearance</th><td><ul>
	<li>115 mL/min</li>
</ul></td></tr><tr><th>Toxicity</th><td>Ceftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma.</td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.8406</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9857</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7235</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8593</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8782</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.6684</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8311</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8404</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8155</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5897</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8112</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7396</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8758</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7009</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8354</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7222</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7979
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8252
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9951
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.6048 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9938
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.659
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Acs dobfar spa</li>
<li>Aurobindo pharma ltd</li>
<li>Wockhardt ltd</li>
<li>Glaxosmithkline</li>
<li>Hospira inc</li>
<li>Eli lilly and co</li>
<li>Baxter healthcare corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Antibioticos Ltd.</li>
<li><a href="http://www.aurobindo.com">Aurobindo Pharma Ltd.</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li>BMH Ltd.</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.gsk.com">GlaxoSmithKline Inc.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.sagentpharma.com">Sagent Pharmaceuticals</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.wockhardtin.com">Wockhardt Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for solution</td><td>Intramuscular</td><td></td></tr><tr><td>Powder, for solution</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00479">Amikacin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00798">Gentamicin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01172">Kanamycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00994">Neomycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00955">Netilmicin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01082">Streptomycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>